Prior to joining GAM Group in November 2010, he was Head of Equity Research at Julius Baer and equity analyst covering the global healthcare sector. Prior to that, he held various positions as a fund manager and equity analyst at Bank Hofmann, Rothschild Bank and Credit Suisse. Christophe Eggmann holds a Master in Business Administration and Economics from the University of Neuchâtel and is a CFA Charterholder. He is based in Zurich.
12 December 20172018 Outlook – The Merits of Active Management
GAM’s investment experts share insights on how active management adds value in their specialist fields.
02 June 2017Biopharma Investment Cycle: Expansion Phase Still in Its Early Innings
Unlocking the secrets of the human genome at the turn of the millennium ushered in a transformative era in drug discovery. Christophe Eggmann looks forward to the next potentially lucrative stage of the secular biopharma investment cycle.
10 January 20172017 Outlook – Contrarian Trades
A number of major political and economic events shaped financial markets in 2016, forcing investors to navigate a landscape of heightened volatility. But with uncertainty likely to continue through 2017, GAM’s investment managers have identified some unique investment opportunities that go against the grain.
05 January 20172017 Outlook – Key Events
With so much happening in parallel across political, economic and financial landscapes, it seems daunting to try to identify the one event that shaped 2016. In the following short statements, our investment experts share their predictions on which events will prove pivotal in 2017.
19 December 20162017 Outlook – The Investment Themes to Watch
2016 was a year of erratic markets and geopolitical shocks that sent fundamentals into the shadows. Bourses moved on speculation and surprise, challenging market participants. GAM’s investment experts put forward their key themes for the year ahead.
15 December 2016Healthcare 2017: The Postelection Comeback
Given an environment conducive to merger and acquisition (M&A) activity, Christophe Eggman, investment director for healthcare equities, looks ahead to 2017 and beyond with a sense of optimism.
12 July 2016Pharma: Healthy Returns Ahead
After a challenging nine months, healthcare investors can look forward to a turnaround in the sector’s fortunes. Christophe Eggmann, investment director for healthcare equities, explains why the sector is set up for a successful second half with plenty of opportunities in biopharma.
23 October 2015Drug pricing threat?
Christophe Eggmann, Investment Director, comments on whether the current drug pricing discussions in the US change his views on healthcare stocks.
15 June 2015Cancer immunotherapy – Turning cancer into a chronic disease
Christophe Eggmann, Investment Director, responsible for GAM’s health innovation strategies explains why cancer immunotherapy is considered a quantum leap in cancer patient survival and has the potential to revolutionize cancer treatment.
Important legal information
The information in this document is given for information purposes only and does not qualify as investment advice. Opinions and assessments contained in this document may change and reflect the point of view of GAM in the current economic environment. No liability shall be accepted for the accuracy and completeness of the information. Past performance is no indicator for the current or future development.